Use of steroidal glycosides, pharmaceutical formulations, use of <i>Furcraea foetida </i>plant extracts, process for producing <i>Furcraea foetida </i>plant extracts and method for treating skin disorders

Abstract

The present invention relates, in its broadest aspects, to steroidal glycosides useful in the treatment of skin disorders. Particularly, the invention relates to the use of certain steroidal glucosides, per se, or in the form aglycona, derivatives of spirostanol, of its precursor furastanol, or mixtures thereof, used in the treatment of skin disorders, for instance, psoriasis. The invention further relates to formulations containing steroidal glycosides, the process of obtaining extract from the Furcraea foetida plant, and a method of treating skin disorders.

Claims

1. A method of treating psoriasis, comprising administering to a subject in need thereof, an effective amount of an extract from the Furcraea foetida plant comprising a compound of the Z-A type, wherein A is a spirostanol structure represented by Formula I ##STR00005## or a furostanol structure represented by Formula II, ##STR00006## wherein: R is H, H or O; and Z is H or one or more saccharide groups having 1 to 12 rings.

2. The method of claim 1, wherein A has a spatial structure represented by Formula III ##STR00007##

3. The method of claim 1, wherein Z is one or more saccharide groups having 6 rings.

4. The method of claim 1, wherein the one or more saccharide groups is selected from the group consisting of: glucose, rhamnose, galactose, fucose, mannose, fructose, ribose, xylose, arabinose, and glucuronide.

5. The method of claim 1, wherein the steroidal glycosides are selected from the group consisting of: (24S,25S)-24-[(-beta-D-glucopyranosyl)oxy]-5 alpha-furoan-3 beta-yl-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl -(1.fwdarw.2)-O-[O-alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta -D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (23S, 25R)-6 alpha-[(Beta-D -glucopyranosyl)oxy]-23-hydroxy-5 alpha-spirostan-3 beta-D-fucoidan; (25R)-26-[(beta-D -glucopyranosyl))oxy]-6 alpha-hydroxy-22 alpha-methoxy-5 alpha-furoan-3 beta-yl-O -beta-D-glucopyranosyl-(1.fwdarw.3)-O-Beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha -1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl -(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-5 alpha-spirostan-3 beta-Yl-O-Beta-D-glucopyranosyl -(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D -Glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-6 alpha-hydroxy-5 alpha-spirostan-3 beta-yl O-Beta-D-glucopyranosyl-(1.fwdarw.3)-O) -[O-alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D -glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside)oxy]-5 alpha-spirostan-12-one (furcreastatin); (23S,25R)-3 beta, 23-dihydroxy-5 alpha-spirostan-6 alpha-yl-Beta -D-glucopyranoside; (25R) -5 alpha-spirostane-3 beta, 6α-di-1-bis-beta-beta-D-glucopyranoside; (23S,25R)-23-hydroxy-5 alpha-spirostane -3 beta, 6α-di-yl bis-Beta-D-glucopyranoside; (25R)-26-[(beta-D-glucopyranosyl)oxy]-22 alpha-methoxy-5 alpha-furoan-3 beta-yl-O -beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O- [O-alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3) ]-O-beta-D-Glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R) -3 beta-[(O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta -D-glucopyranosyl-(1.fwdarw.2)-O-[O-Alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1 .fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranosyl)oxy]-26 a-[(beta -D-glucopyranosyl)oxy ]-22-methoxy-5 a-furoan-12-one; (25R) -22 alpha-methoxy -5 alpha -furoan -3 beta, 6α, 26-triyl tris-beta-D-glucopyranoside; and combinations thereof.

6. The method of claim 1, wherein Z is a hexasaccharide represented by Formula IV ##STR00008##

7. The method of claim 1, wherein the steroidal glycoside is (25R)-6 Alpha-hydroxy-5 Alpha-espirostan-3 beta-yl O-beta-D-glucopyranosyl-(1.fwdarw.3) -O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-Alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D -glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranosyl.

8. The method of claim 1, wherein the extract is administered in the form of a pharmaceutical composition comprising the extract and a pharmaceutically acceptable carrier.

Description

EXAMPLE 1—PROCESS FOR OBTAINING THE EXTRACT

(1) 30 parts in weight of ethanol and 70 parts in weight of Furcraea foetida leaves pulp, previously crushed, are blended in and left in contact together for a certain amount of time, for instance, until 48 hours. It is followed by filtration.

EXAMPLE 2—FORMULATION AND TREATMENT

(2) The liquid of example 1 is formulated as a lotion, which is applied, periodically upon skin areas affected by psoriasis. After a few applications, it can be observed that the disease regression, both visually and concerning the pruritus, occurs in a fast and effective way.

(3) A person skilled in the art will be able to, from the information and examples provided herein, perform the invention in equivalent forms, not expressly disclosed, however, with the same, or substantially the same function, and the same, or substantially the same results, even though they are under the protective scope of the attached set of claims.